NCT02113878 2024-11-05
Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck
Dana-Farber Cancer Institute
Phase 1 Completed
Clinical Trials
30 trialsNCT01397877 2023-09-06
ENDOPIK
ARCAGY/ GINECO GROUP
Phase 2 Completed
NCT01570296 2023-03-29
BKM120
National Cancer Centre, Singapore
Phase 1 Completed
NCT02756247 2022-10-10
A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT01540253 2022-07-22
PI3K Inhibitor BKM120 and Docetaxel in Treating Patients With Advanced Solid Tumor That is Locally Advanced, Cannot Be Removed By Surgery, or Metastatic
Roswell Park Cancer Institute
Phase 1 Completed
NCT02049541 2022-06-30
Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT02220855 2022-04-11
A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas
Indiana University
Phase 2 Completed
NCT01816984 2021-10-05
PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
University of Chicago
Phase 1/2 Completed
NCT01623349 2021-02-10
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
NCT01629615 2020-10-28
A Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer
SOLTI Breast Cancer Research Group
Phase 2 Completed
NCT01349660 2020-06-17
Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme
SCRI Development Innovations, LLC
Phase 1/2 Completed
NCT02128724 2019-08-01
BKM120
University of Oxford
Phase 1 Completed
NCT01737450 2019-06-24
PIK-ORL
Centre Leon Berard
Phase 2 Completed
NCT01339052 2019-03-19
Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01487265 2019-03-06
Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib
SCRI Development Innovations, LLC
Phase 2 Completed
NCT01790932 2019-01-23
BKM120 For Triple Negative Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01719250 2018-10-09
Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Mayo Clinic
Phase EARLY_PHASE1 Completed
NCT02439489 2018-06-20
Study of the Combination of BKM120 and Cisplatin or Carboplatin in Patients With Advanced Solid Tumors
Fondazione Michelangelo
Phase 1 Completed
NCT02404844 2018-04-20
PIKTAM
University Hospital, Essen
Phase 2 Completed
NCT01470209 2018-03-19
A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies
Emory University
Phase 1 Completed
NCT02194049 2018-01-09
Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung Cancer
University of California, Davis
Phase 1 Completed
NCT02301364 2017-10-19
Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01571024 2017-04-26
BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 1 Completed
NCT01297452 2017-03-31
BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT01339442 2017-01-25
BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer
Washington University School of Medicine
Phase 1 Completed
NCT01304602 2017-01-06
A Trial of Irinotecan and BKM120 in Previously Treated Advanced Colorectal Cancer
University of Kansas Medical Center
Phase 1 Completed
NCT01396499 2016-11-01
Study to Assess Safety, Tolerability and Preliminary Efficacy of BKM120, PI3K Kinase Inhibitor, With Advanced Leukemias
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01723800 2016-09-20
PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung Cancer
City of Hope Medical Center
Phase 1 Completed
NCT01248494 2016-07-25
PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase 1 Completed
NCT01513356 2014-04-02
Pharmacodynamic Study of BKM120 in Breast Cancer
Grupo Hospital de Madrid
Phase EARLY_PHASE1 Completed